Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
Status:
Recruiting
Trial end date:
2023-12-16
Target enrollment:
Participant gender:
Summary
Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study
designed to evaluate the efficacy and safety of eblasakimab in participants with
moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study
consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible
participants will be randomized into one of the 2 treatment arms.